Effect of Niaoduqing granules on residual renal function and levels of fibronectin and TGF-β1 in peritoneal dialysate of peritoneal dialysis patients

doi:10.3877/cma.j.issn.2095-3216.2023.04.004

Abstract

Abstract:

Objective

To investigate the effect of Niaoduqing granules on residual renal function (RRF) and levels of fibronectin (FN) and TGF-β1 in peritoneal dialysate of peritoneal dialysis patients.

Methods

A total of 103 end-stage kidney disease patients who underwent PD treatment in the four hospitals were enrolled, and randomly divided into an experimental group of 52 cases and a control group of 51 cases. The control group received PD treatment, while the experimental group received oral Niaoduqing granules on the basis of PD treatment for 12 months. The two groups were compared in changes of RRF, urine volume, residual Kt/V, residual creatinine clearance rate (Ccr), FN, and TGF-β1 before and after the treatment.

Results

After 12 months of treatment, the levels of RRF, residual Kt/V, and residual Ccr were lower in both groups (P<0.05), but were higher in the experimental group than in the control group (P<0.05). In addition, after treatment, the levels of FN and TGF-β1 in the peritoneal dialysate of the experimental group decreased significantly, and were also lower than those of the control group (all P<0.01).

Conclusion

Niaoduqing granules improved the RRF of the PD patients, and reduced the expression of FN and TGF-β1 implicating that Niaoduqing granules might also have an inhibitory effect on peritoneal fibrosis.

Key words: Niaoduqing granules, Peritoneal dialysis, Residual renal function, Peritoneal fibrosis

Yangyan Luo, Shaoqing Wang, Fang Gao, Yan Shen, Wanjun Zhang, Li Li. Effect of Niaoduqing granules on residual renal function and levels of fibronectin and TGF-β1 in peritoneal dialysate of peritoneal dialysis patients[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2023, 12(04): 200-204.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2023.04.004

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2023/V12/I04/200

Figures/Tables 5

References 14

[1]	赵庆云，吴乃超，杨洪涛. 中医药治疗腹膜透析致腹膜纤维化研究进展[J]. 辽宁中医药大学学报，2019, 21(12): 93-95.
[2]	钱虹利，廖威，孟立锋，等. 尿毒清颗粒对腹膜透析患者临床疗效及安全性的系统评价与Meta分析[J]. 辽宁中医杂志，2020, 47(2): 33-40.
[3]	Lu YH, Hwang JC, Jiang MY, et al. Comparison of the impact of "fast decline" in residual renal function and "initial anuria" on long-term outcomes in CAPD Patients [J]. Perit Dial Int, 2015, 35(2): 172-179.
[4]	Maiorca R, Brunori G, Zubani R, et al. Predictive value of dialysis adequacy and nutritional indices for mortality and morbidity in CAPD and HD patients A longitudinal study [J]. Nephrol Dial Transplant, 1995, 10(12): 2295-2305.
[5]	Canada-USA (CANUSA) Peritoneal Dialysis Study Group. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes [J]. J Am Soc Nephrol, 1996, 7(2): 198-207.
[6]	Bargman JM, Thorpe KE, Churchill DN. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study [J]. J Am Soc Nephrol, 2001, 12(10): 2158-2162.
[7]	Li XJ, Liu H, Sun L, et al. MicroRNA-302c modulates peritoneal dialysis associated fibrosis by targeting connective tissue growth factor [J]. J Cell Mol Med, 2019, 23(4): 2372-2383.
[8]	Loureiro J, Gónzalez-Mateo G, Jimenez-Heffernan J, et al. Are the mesothelial-to-mesenchymal transition, sclerotic peritonitis syndromes, and encapsulating peritoneal sclerosis part of the same process? [J]. Int J Nephrol, 2013, 2013: 263285.
[9]	Zhou Q, Yang M, Lan H, et al. MiR-30a negatively regulates TGF-β1-induced epithelial-mesenchymal transition and peritoneal fibrosis by targeting Snai1 [J]. Am J Pathol, 2013, 183(3): 808-819.
[10]	Li C, Ren Y, Jia X, et al. Twist overexpression promoted epithelial-to-mesenchymal transition of human peritoneal mesothelial cells under high glucose [J]. Nephrol Dial Transplant, 2012, 27(11): 4119-4124.
[11]	Frangogiannis N. Transforming growth factor-β in tissue fibrosis [J]. J Exp Med, 2020, 217(3): e20190103.
[12]	姚素花，麦李明，石俊婷. 百令胶囊对尿毒症腹膜透析患者腹透液中转化生长因子-β1、纤维连接蛋白表达的影响[J]. 转化医学杂志，2017, 6(5): 266-268.
[13]	官继超，王时敏，单娟萍. 替米沙坦联合尿毒清对腹膜透析患者残余肾功能的影响[J]. 中国中西医结合肾病杂志，2013, 14(11): 993-995.
[14]	Beladi Mousavi SS, Hayati F, Valavi E, et al. Comparison of survival in patients with end-stage renal disease receiving hemodialysis versus peritoneal dialysis [J]. Saudi J Kidney Dis Transpl, 2015, 26(2): 392-397.

项目	对照组(n＝51)	试验组(n＝52)	χ²值/t值	P值
性别(男/女)	27/24	30/22	0.08	0.77
年龄(岁)	56.8±7.25	54.9±7.86	1.26	0.21
透析龄(月)	23.4±7.12	22.8±7.23	0.42	0.67
基础疾病[例(%)]
肾小球肾炎	22(43.1)	24(46.2)	0.09	0.76
糖尿病	19(37.3)	18(34.6)	0.08	0.78
高血压	7(13.7)	6(11.5)	0.11	0.74
多囊肾	1(2.0)	1(1.9)	<0.01	0.98
其他	2(3.9)	3(5.8)	0.19	0.66

项目	对照组(n＝51)	试验组(n＝52)	χ²值/t值	P值
性别(男/女)	27/24	30/22	0.08	0.77
年龄(岁)	56.8±7.25	54.9±7.86	1.26	0.21
透析龄(月)	23.4±7.12	22.8±7.23	0.42	0.67
基础疾病[例(%)]
肾小球肾炎	22(43.1)	24(46.2)	0.09	0.76
糖尿病	19(37.3)	18(34.6)	0.08	0.78
高血压	7(13.7)	6(11.5)	0.11	0.74
多囊肾	1(2.0)	1(1.9)	<0.01	0.98
其他	2(3.9)	3(5.8)	0.19	0.66

项目	对照组(n＝47例)	试验组(n＝49例)	χ²值/t值	P值
性别(男/女)	25/22	28/21	0.15	0.85
年龄(岁)	55.2±13.5	54.8±14.2	0.14	0.88
透析龄(月)	22.7±8.56	23.6±9.66	0.48	0.63
基础疾病[例(%)]
肾小球肾炎	22(46.8)	24(49.0)	0.05	0.83
糖尿病	16(34.0)	16(32.7)	0.02	0.88
高血压	7(14.9)	6(12.2)	0.14	0.70
多囊肾	0(0)	1(2.0)	0.96	0.32
其他	2(4.3)	2(4.1)	<0.01	0.96
血压(mmHg)
收缩压	140.3±19.6	141.7±20.5	0.34	0.73
舒张压	90.7±9.5	91.1±10.1	0.19	0.84
实验室指标
血红蛋白(g/L)	101.4±24.3	103.6±21.1	0.47	0.63
白蛋白(g/L)	30.3±3.5	31.6±3.2	1.90	0.06
血钙(mmol/L)	2.15±0.2	2.21±0.2	1.47	0.15
血磷(mmol/L)	1.62±0.43	1.59±0.39	0.36	0.72
甲状旁腺激素(pg/ml)	278.4±204.1	284.7±201.3	0.15	0.88
C反应蛋白(mg/L)	1.9±0.6	2.1±0.5	1.78	0.08
24 h尿蛋白(g)	1.8±0.8	1.9±0.6	0.69	0.48
残肾指标
残余肾功能(ml/min)	7.6±2.2	7.8±1.6	0.51	0.61
尿量(ml)	887.9±430.5	919.9±472.3	0.35	0.73
残肾Kt/V	0.81±0.21	0.87±0.20	1.43	0.15
残肾Ccr(L/W/1.73 m²)	32.3±5.2	31.5±6.0	0.69	0.48
透析充分性相关指标
腹膜Kt/V	0.98±0.18	0.94±0.19	1.06	0.29
腹膜Ccr [L/(W·1.73 m²)]	37.5±10.7	38.1±9.9	0.28	0.77
总Kt/V	1.83±0.14	1.85±0.12	0.75	0.45
总Ccr[L/(W·1.73 m²)]	69.2±8.9	68.8±10.3	0.20	0.84
24 h超滤量(ml)	600.7±210.6	619.8±201.7	0.45	0.65

项目	对照组(n＝47例)	试验组(n＝49例)	χ²值/t值	P值
性别(男/女)	25/22	28/21	0.15	0.85
年龄(岁)	55.2±13.5	54.8±14.2	0.14	0.88
透析龄(月)	22.7±8.56	23.6±9.66	0.48	0.63
基础疾病[例(%)]
肾小球肾炎	22(46.8)	24(49.0)	0.05	0.83
糖尿病	16(34.0)	16(32.7)	0.02	0.88
高血压	7(14.9)	6(12.2)	0.14	0.70
多囊肾	0(0)	1(2.0)	0.96	0.32
其他	2(4.3)	2(4.1)	<0.01	0.96
血压(mmHg)
收缩压	140.3±19.6	141.7±20.5	0.34	0.73
舒张压	90.7±9.5	91.1±10.1	0.19	0.84
实验室指标
血红蛋白(g/L)	101.4±24.3	103.6±21.1	0.47	0.63
白蛋白(g/L)	30.3±3.5	31.6±3.2	1.90	0.06
血钙(mmol/L)	2.15±0.2	2.21±0.2	1.47	0.15
血磷(mmol/L)	1.62±0.43	1.59±0.39	0.36	0.72
甲状旁腺激素(pg/ml)	278.4±204.1	284.7±201.3	0.15	0.88
C反应蛋白(mg/L)	1.9±0.6	2.1±0.5	1.78	0.08
24 h尿蛋白(g)	1.8±0.8	1.9±0.6	0.69	0.48
残肾指标
残余肾功能(ml/min)	7.6±2.2	7.8±1.6	0.51	0.61
尿量(ml)	887.9±430.5	919.9±472.3	0.35	0.73
残肾Kt/V	0.81±0.21	0.87±0.20	1.43	0.15
残肾Ccr(L/W/1.73 m²)	32.3±5.2	31.5±6.0	0.69	0.48
透析充分性相关指标
腹膜Kt/V	0.98±0.18	0.94±0.19	1.06	0.29
腹膜Ccr [L/(W·1.73 m²)]	37.5±10.7	38.1±9.9	0.28	0.77
总Kt/V	1.83±0.14	1.85±0.12	0.75	0.45
总Ccr[L/(W·1.73 m²)]	69.2±8.9	68.8±10.3	0.20	0.84
24 h超滤量(ml)	600.7±210.6	619.8±201.7	0.45	0.65

组别	例数	残余肾功能(ml/min)				尿量(ml)
组别	例数	0月	12月	t值	P值	0月	12月	t值	P值
对照组	47	7.6±2.2	4.8±1.7	6.90	<0.01	887.9±430.5	560.7±405.8	3.79	<0.01
试验组	49	7.8±1.6	7.1±1.8	2.03	0.04	919.9±472.3	733.7±433.8	2.03	0.04
t值		0.51	6.43			0.35	2.01
P值		0.61	<0.01			0.73	0.04
组别	例数	残肾Kt/V				残肾内生肌酐清除率[L/(W·1.73 m²)]
组别	例数	0月	12月	t值	P值	0月	12月	t值	P值
对照组	47	0.81±0.21	0.54±0.17	6.85	<0.001	32.3±5.2	23.4±4.1	9.21	<0.01
试验组	49	0.87±0.20	0.72±0.19	3.81	<0.001	31.5±6.0	25.6±4.1	5.68	<0.01
t值		1.43	4.84			0.69	2.62
P值		0.15	<0.01			0.48	<0.01

Please choose a citation manager

Content to export